Lotter Claudia, Stierli Megan Anna, Puligilla Ramya Deepthi, Huwyler Jörg
Department of Pharmaceutical Technology, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland.
Department of Pharmaceutical Technology, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland.
Eur J Pharm Biopharm. 2025 Apr;209:114674. doi: 10.1016/j.ejpb.2025.114674. Epub 2025 Feb 21.
Lipid nanoparticles (LNPs) have gained much attention as non-viral gene delivery systems due to their large payload capacity, reduced immunogenicity, and cost-effective manufacturing. Surface modification of LNPs by covalent attachment of receptor ligands can improve their tissue specificity and reduce off-target effects. In the present work, DNA-LNPs were therefore designed to target breast cancer, particularly the invasive HER2-positive subtype. Targeting was mediated by trastuzumab (Herceptin®) a monoclonal antibody binding to the extracellular domain of the human epidermal growth factor receptor protein (HER2). To overcome intrinsic trastuzumab resistance for some patients with HER2 positive breast cancer, a dual-targeting strategy was employed by combining Herceptin with folate to enhance LNP uptake by cancer cells. Dual-targeted LNPs encapsulating plasmid DNA, coding for a fluorescent reporter protein (tdTomato or EGFP), were prepared using folate-conjugated PEGylated lipids. Subsequently, thiolated Herceptin was conjugated to the surface of the LNPs. At an N/P ratio of 6, small and uniform targeted LNPs were obtained, with a slightly negative ζ-potential. Cellular uptake and transgene expression were characterized invitro using three breast cancer cell lines (MCF7, MDA-mb453, SKBR3), which express varying level of the HER2 receptor. Cellular uptake correlated with HER2 expression levels and was significantly increased when Herceptin was combined with folate. In all tested breast cancer cell lines, dual-targeted LNPs led to an enhanced transgene expression compared to single-targeted LNPs. Furthermore, invivo zebrafish xenograft studies confirmed superior targeting and transfection efficiency of Dual-LNPs under physiological conditions. Our findings highlight the superior performance of dual-targeted LNPs to deliver a DNA expression plasmid to HER2 positive breast cancer cells, emphasizing their potential as an improved targeting and transfection strategy.
脂质纳米颗粒(LNPs)作为非病毒基因递送系统受到了广泛关注,因为它们具有较大的有效载荷能力、降低的免疫原性以及成本效益高的制造工艺。通过共价连接受体配体对LNPs进行表面修饰可以提高其组织特异性并减少脱靶效应。因此,在本研究中,设计了DNA-LNPs来靶向乳腺癌,特别是侵袭性HER2阳性亚型。靶向作用由曲妥珠单抗(赫赛汀®)介导,这是一种与人类表皮生长因子受体蛋白(HER2)细胞外结构域结合的单克隆抗体。为了克服一些HER2阳性乳腺癌患者的内在曲妥珠单抗耐药性,采用了双靶向策略,将赫赛汀与叶酸结合以增强癌细胞对LNP的摄取。使用叶酸偶联的聚乙二醇化脂质制备了包裹编码荧光报告蛋白(tdTomato或EGFP)的质粒DNA的双靶向LNPs。随后,将硫醇化的曲妥珠单抗偶联到LNPs表面。在N/P比为6时,获得了小而均匀的靶向LNPs,其ζ电位略为负值。使用三种表达不同水平HER2受体的乳腺癌细胞系(MCF7、MDA-mb453、SKBR3)在体外对细胞摄取和转基因表达进行了表征。细胞摄取与HER2表达水平相关,并且当曲妥珠单抗与叶酸结合时显著增加。在所有测试的乳腺癌细胞系中,与单靶向LNPs相比,双靶向LNPs导致转基因表达增强。此外,体内斑马鱼异种移植研究证实了双靶向LNPs在生理条件下具有优异的靶向和转染效率。我们的研究结果突出了双靶向LNPs向HER2阳性乳腺癌细胞递送DNA表达质粒的卓越性能,强调了它们作为一种改进的靶向和转染策略的潜力。